Compare AVIR & GHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVIR | GHY |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.9M | 520.5M |
| IPO Year | 2020 | N/A |
| Metric | AVIR | GHY |
|---|---|---|
| Price | $5.41 | $11.81 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 281.6K | 148.9K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.58% |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $11.25 |
| 52 Week High | $6.45 | $13.72 |
| Indicator | AVIR | GHY |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 44.02 |
| Support Level | $5.03 | $11.25 |
| Resistance Level | $6.37 | $12.89 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 19.46 | 24.64 |
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.